Preventive role of PD-1 on MPTP-induced dopamine depletion in mice.
Many current studies of Parkinson's disease (PD) suggest that inflammation is involved in the neurodegenerative process. PD-1, a traditional Korean medicine, used to treat various brain diseases in Korea. This study was designed to investigate the effect of PD-1 extract in the Parkinson's model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesioned mice. The MPTP administration caused the dopamine neuron loss in the striatum and substantia nigra pars compacta (SNpc), which was demonstrated by a depletion of tyrosine hydroxylase (TH). In addition, a reduction of bcl-2 expression with elevation of bax expression, caspase-3 activation, and release of cytochrome c into cytosol in dopaminergic neurons of SNpc were noted. Oral administration of PD-1 extract (50 and 100 mg kg(-1)) attenuated the MPTP-induced depletion of TH proteins in the striatum and SNpc and prevented the apoptotic effects. These results indicate that PD-1 extract is able to protect dopaminergic neurons from MPTP-induced neuronal death, with important implications for the treatment of PD.
Jung
Hyo Won
HW
Oriental Medicine R&D Center, Dongguk University, Gyeongju, South Korea.
Son
Hye Young
HY
Jin
Guang-Zhen
GZ
Park
Yong-Ki
YK
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D003342:Corpus Striatum / Q000166:cytology / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D004298:Dopamine / Q000378:metabolism*; D006801:Humans; D007723:Korea; D020267:MPTP Poisoning / Q000378:metabolism*; D055670:Medicine, Korean Traditional; D051379:Mice; D008810:Mice, Inbred C57BL; D009474:Neurons / Q000166:cytology / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D018696:Neuroprotective Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D028321:Plant Preparations / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D013378:Substantia Nigra / Q000166:cytology / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
D018696:Neuroprotective Agents; C550287:PD-1 herbal preparation; D028321:Plant Preparations; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine